Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy

Samlowski, Wolfram; Adajar, Camille

doi:10.1186/s12885-021-08906-1

Table 2 Melanoma characteristics from start of TT + CKI treatment

From: Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy

Pt	Metastases	additional characteristics	Brain metastases	LDH	PD-1	TT	TT Toxicity	CTCAE grade	R2 (mo)	Outcome
1	SC, LN		+	↑	P	D	nausea, anemia, interstitial nephritis	G4	20.3	CR-Off
2	SC		–	nl	N	DT	chronic nausea	G1	11.2	CR-Off
3	SC, LN, adrenal, liver, spleen, lung, bone	bulky LN disease	–	nl	N	E	hand/foot syndrome, fatigue, floaters	G2	22.6	CR-Off
4	SC, LN,lung		–	nl	P	DT/EB	diarrhea, rash	G2	44.2	CR-Off
5	SC bone		–	nl	N	EB	diarrhea	G2	7.4	CR-TT
6	SC, LN, liver, lung, bone	miliary metastases	+	↑	N	D	none-sudden death	G5	0.4	CR-sudden death
7	SC, LN	bulky LN disease	–	nl	N	DT/EB	rash, keratoacanthomas	G1	22.9	CR-TT
8	SC, LN	bulky LN disease	–	nl	N	DT	seronegative arthritis fatigue	G3	35.5	CR-Off
9	SC, LN, lung bone	miliary metastases	–	nl	N	D	hand foot syndrome, keratoacanthomas	G1	33.4	DOD
10	SC, LN	bulky LN disease	–	↑	N	D	visual blurring, photophobia, DVT, seronegative arthritis	G3	50.6	CR-Off
11	SC, LN, peritoneum, bone	miliary metastases	–	nl	N	D	none	G0	64.6	CR-Off
12	SC, LN, lung bone	miliary metastases	–	nl	N	D	pulmonary granulomas	G2	51.9	CR-Off
13	SC, LN	bulky SC disease	–	nl	N	DT	diarrhea	G2	33.2	CR-Off
14	SC, LN, peritoneal		–	nl	N	EB	nausea, weight loss, abdominal discomfort, shooting pains	G2	18.8	PD-alive
15	SC, intramuscular, LN, peritoneum, spleen, bone	miliary metastases	+	↑	N	EB/ET	None	G0	6.3	DOD
16	SC, LN		–	↑	N	EB/DT	rash, fever, arthralgias, fatigue	G1	9.0	DOD
17	SC, LN		–	nl	N	DT/VC	joint aches, maculopapular rash, pruritis	G2	8.5	DOD
18	SC, LN, bone		+	nl	P	DT	arthralgia	G1	6.3	DOD
19	LN, adrenal, liver, spleen, lung, bone		+	↑	N	DT	none	G0	0.6	DOD
20	lung		–	nl	P	DT	none	G0	15.4	DOD
21	SC, intramuscular, LN, lung, liver, spleen, adrenal		+	↑	N	DT	hypotension, anemia	G1	7.7	DOD
22	lung, liver, LN, bone		+	↑	N	DT/EB	ataxia, sensory motor neuropathy, immune nephritis	G4	9.7	DOD
23	lung		+	nl	N	D	none	G0	2.1	DOD

SC subcutaneous, LN lymph nodes, + present, − absent, ↑ elevated, nl normal; Immunotherapy: N nivolumab, P pembrolizumab, TT Targeted Therapy, D dabrafenib, T trametinib, E encorafenib, B binimetinib, V vemurafenib, C cobimetinib, CR-Off ongoing complete response, off all therapy, CR-TT complete response continuing targeted therapy, DOD dead of disease, PD-alive progressive disease, remains alive

Back to article page

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com

BMC Cancer

Contact us